Oncology
Latest news
915 articles · 20 / page
Optimizing Adjuvant Therapy for KIT Exon 9-Mutated Gastrointestinal Stromal Tumors: Evidence from a Global Multicenter Synthesis
This review synthesizes the latest evidence on adjuvant imatinib for KIT exon 9-mutated GISTs, highlighting the landmark 2026 international study that confirms improved survival and challenges previous dosing paradigms in the adjuvant setti
KEYVIBE-010: Why Adding TIGIT Inhibition to Pembrolizumab Failed to Benefit High-Risk Resected Melanoma Patients
The Phase 3 KEYVIBE-010 trial demonstrates that adding vibostolimab to pembrolizumab in the adjuvant setting for melanoma does not improve outcomes, instead yielding a higher recurrence rate and increased toxicity, reinforcing pembrolizumab
MRI-Guided Personalization of Chemotherapy for HER2-Positive Breast Cancer: Insights from the TRAIN-3 Trial
The TRAIN-3 study reveals that using MRI to monitor treatment response allows for shorter chemotherapy durations in HER2-positive breast cancer patients, achieving high 3-year event-free survival while significantly reducing toxicity and im
Risk Stratification in PSMA PET-Staged Oligorecurrent Prostate Cancer: Clinical Synthesis of the PORTAL Nomogram and Metastasis-Directed Therapy
This review analyzes the PORTAL study’s nomogram for predicting ADT-free survival in oligorecurrent prostate cancer, synthesizing evidence on PSMA PET-guided SBRT and the clinical utility of risk-based patient selection.
Rethinking the Standard: Does Less Mean More for Frail Elderly Patients with Head and Neck Cancer?
The ELAN-RT trial demonstrates that hypofractionated split-course radiotherapy is non-inferior to standard fractionation for 6-month locoregional response in frail older patients, providing a less toxic alternative, though standard therapy
Redefining the Standard of Care in High-Risk Resected SCCHN: Insights from the GORTEC 2018-01 NIVOPOST-OP Trial
This review analyzes the Phase 3 NIVOPOST-OP trial, demonstrating that adding nivolumab to postoperative chemoradiotherapy significantly improves disease-free survival in high-risk SCCHN patients, establishing a potential new therapeutic st
Savolitinib Plus Osimertinib Redefines Second-Line Therapy for MET-Amplified, EGFR-Mutant NSCLC: Insights from the Phase 3 SACHI Trial
The Phase 3 SACHI trial demonstrates that the combination of savolitinib and osimertinib significantly extends progression-free survival compared to chemotherapy in patients with MET-amplified, EGFR-mutated non-small-cell lung cancer who pr
Adjunctive Ultrasonography Reduces Advanced Breast Cancer Risk in Women Aged 40-49: Long-Term Evidence from J-START
A prespecified secondary analysis of the J-START trial reveals that adding ultrasonography to mammography for women aged 40-49 significantly reduces the long-term cumulative incidence of advanced breast cancer, particularly in populations w
PAXG Challenges mFOLFIRINOX as the New Standard for Preoperative Pancreatic Cancer Care: Insights from the CASSANDRA Trial
The Phase 3 CASSANDRA trial reveals that the four-drug PAXG regimen significantly improves event-free survival compared to mFOLFIRINOX in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma, potentially redefi
Mobile App-Led Self-Acupressure: A Scalable Solution for Ovarian Cancer-Related Fatigue
A phase 3 randomized clinical trial demonstrates that 6 weeks of mobile app-guided self-acupressure significantly and sustainably reduces fatigue in ovarian cancer survivors compared to usual care, providing a safe, low-cost digital health
Beyond Information Delivery: Why Survivorship Care Plans Alone May Not Reduce Cardiovascular Risk in Cancer Survivors
This article examines the CHIIP study, a randomized clinical trial evaluating whether survivorship care plan-based counseling improves cardiovascular risk factor control in childhood cancer survivors. Findings suggest that while documentati
Letrozole, Abemaciclib, and Metformin Triplet Therapy Shows Robust Activity in ER-Positive Endometrioid Endometrial Cancer
A phase 2 trial demonstrates that combining letrozole, abemaciclib, and metformin achieves a 32% response rate and 60% clinical benefit rate in ER+ endometrioid endometrial cancer, with notable efficacy in CTNNB1-mutated tumors and an inter
China’s Workforce Faces Alarming Cancer Risk Profiles: New Baseline Data from the WECAN Project
A cross-sectional analysis of 841 workers across China reveals a high prevalence of modifiable cancer risk factors, including poor diet, smoking, and low screening rates. The study highlights significant regional disparities, calling for ta
Perioperative Enfortumab Vedotin and Pembrolizumab: A Practice-Changing Advance for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
The Phase 3 KEYNOTE-905/EV-303 trial demonstrates that perioperative enfortumab vedotin plus pembrolizumab significantly improves event-free survival (HR 0.40) and overall survival (HR 0.50) compared to surgery alone in cisplatin-ineligible
Optimizing Prognosis: The New AJCC Version 9 Staging for Salivary Gland Carcinoma
The proposed AJCC/UICC Version 9 staging for salivary gland carcinoma shifts toward a unified, specific system using lymph node count and extranodal extension, significantly improving prognostic accuracy for both major and minor salivary gl
Precision Oncology Meets Artificial Intelligence: Navigating Ancestry-Associated Variability in Digital Pathology for EGFR Prediction
This review evaluates the generalizability of AI pathology models in predicting EGFR mutations, highlighting significant performance variations across genetic ancestries and specimen types, and their role in clinical triage.
Salvage Focal Therapy vs. Radical Prostatectomy: Comparable 10-Year Survival with Dramatically Reduced Morbidity
A landmark multicenter study indicates that salvage focal therapy (sFT) achieves long-term cancer-specific survival comparable to salvage radical prostatectomy (sRP) while significantly lowering the risk of major perioperative complications
Preoperative ctDNA Detects Occult Nodal Metastasis and Predicts Recurrence in Early-Stage Esophageal Squamous Cell Carcinoma
A multi-center study demonstrates that preoperative ctDNA detection significantly outperforms traditional clinical criteria in predicting nodal upstaging and survival outcomes for patients with clinical stage I/II ESCC, potentially redefini
GnRH Agonists Linked to Accelerated Coronary Plaque Progression Compared to Antagonists in Prostate Cancer Patients
A randomized clinical trial demonstrates that the GnRH agonist leuprolide leads to significantly greater coronary plaque progression, specifically noncalcified plaque, compared to the antagonist relugolix in men with prostate cancer, offeri
Pembrolizumab Dominates the HNC Market While Immune-Related Adverse Events Persist in Real-World Practice
A large-scale cohort study of 47,365 head and neck cancer patients reveals a significant market shift toward pembrolizumab and a 41.2% incidence of immune-related adverse events, though severe toxicities remain rare and are linked to specif
Browse by specialty
Open language-specific specialty feeds and department pages.